Paper Details

  1. Home
  2. Paper Details

Long-term safety and efficacy of imatinib in pulmonary arterial hypertension.

Author: BarstRobyn J, ChangHyuk-Jae, Dario VizzaCarmine, FelserJames M, FrantzRobert P, FrostAdaani E, FukumotoYoshihiro, GaliéNazzareno, GhofraniHossein-Ardeschir, HassounPaul M, HoeperMarius M, KloseHans, LawrenceDavid, MatsubaraHiromi, MorrellNicholas W, PeacockAndrew J, PfeiferMichael, QuinnDeborah A, SimonneauGérald, TapsonVictor F, TorresFernando, YangWei

Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Imatinib, a protein kinase inhibitor, has shown promise in improving hemodynamics and exercise capacity in pulmonary arterial hypertension (PAH) patients who have not responded well to conventional PAH therapies.
Paper Details　
Original Abstract of the Article :
Imatinib is an oral inhibitor of several protein kinases implicated in the pathophysiology of pulmonary hypertension. Treatment with imatinib resulted in improved hemodynamics and exercise capacity in a controlled trial (Imatinib [QTI571] in Pulmonary Arterial Hypertension, a Randomized Efficacy Stu...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.healun.2015.05.025

データ提供：米国国立医学図書館（NLM）

Imatinib: A Potential Hope for Pulmonary Arterial Hypertension

The treatment of [pulmonary arterial hypertension (PAH)] presents unique challenges, as researchers seek effective ways to manage this complex and often debilitating condition. This article explores the potential of [imatinib], a [protein kinase inhibitor], as a treatment option for PAH.

Imatinib: Targeting the Mechanisms of PAH

The article highlights the rationale for using imatinib in PAH, emphasizing its ability to inhibit key protein kinases implicated in the disease's pathophysiology. This targeted approach offers a potential mechanism for addressing the underlying causes of PAH and potentially improving patient outcomes.

A New Path Forward: Imatinib's Potential in PAH Treatment

This article provides encouraging evidence for imatinib as a potential therapeutic option for PAH. The study results, demonstrating its effectiveness in improving hemodynamics and exercise capacity, offer hope for patients who have not responded adequately to conventional PAH therapies.

Dr. Camel's Conclusion

The journey to effective PAH treatment is a challenging one, navigating the complexities of this debilitating condition. This article explores the potential of imatinib, a promising drug that could target key pathways involved in PAH. While further research is needed, this study offers a glimmer of hope for patients seeking new and effective treatment options.

Date :
  1. Date Completed 2016-08-16
  2. Date Revised 2022-01-29
Further Info :

Pubmed ID

26210752

DOI: Digital Object Identifier

10.1016/j.healun.2015.05.025

Related Literature

Article Analysis
・Effective treatment of pulmonary hypertension
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.